Monoclonal antibody production by hybridoma growth in Freund's adjuvant primed mice.
Incomplete Freund's adjuvant was used as a priming agent prior to the injection of hybridoma cells in mice to expand monoclonal antibody production. Two hybridoma cell lines, FDO28B (IgG1) and FDO31C (IgM), which produce monoclonal antibodies reactive towards human placenta, were used. Monoclonal antibody was detected in the ascites fluids by agarose gel electrophoresis. It was found that the time interval between adjuvant priming and cell injection could be reduced to 1 day, allowing collection of ascites fluid containing monoclonal antibody within 2 weeks of priming. In addition, as few as 1 X 10(5) hybridoma cells were needed to collect approximately 5-7 ml of ascites fluid containing antibody detectable by gel electrophoresis. Thus priming with incomplete Freund's adjuvant enables production of large amounts of monoclonal antibody in a short time using a low number of hybridoma cells.
D000818:Animals; D000911:Antibodies, Monoclonal / Q000096:biosynthesis*; D001201:Ascites / Q000209:etiology; D001202:Ascitic Fluid / Q000276:immunology; D002460:Cell Line; D005620:Freund's Adjuvant / Q000276:immunology* / Q000633:toxicity; D006825:Hybridomas / Q000276:immunology* / Q000637:transplantation; D007274:Injections, Intraperitoneal; D051379:Mice; D008807:Mice, Inbred BALB C / Q000276:immunology; D010534:Peritoneal Neoplasms / Q000139:chemically induced / Q000150:complications; D010954:Plasmacytoma / Q000139:chemically induced / Q000150:complications; D013997:Time Factors
D000911:Antibodies, Monoclonal; D005620:Freund's Adjuvant